The spectrum of monogenic autoinflammatory syndromes: Understanding disease mechanisms and use of targeted therapies

Current Allergy and Asthma Reports

Volumn 8, Issue 4, 2008, Pages 288-298

  Glaser, Rachel L ^b   Goldbach Mansky, Raphaela ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; AZITHROMYCIN; BISPHOSPHONIC ACID DERIVATIVE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GAMMA INTERFERON; GLUCOCORTICOID; INFLIXIMAB; INTERLEUKIN 1BETA; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHOTREXATE; MEVALONATE KINASE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; SIMVASTATIN; THALIDOMIDE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR 1; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR ALPHA;

AMYLOIDOSIS; ARTHRALGIA; ARTHRITIS; ARTICLE; AUTOINFLAMMATORY DISEASE; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS; CINCA SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; CRYOPYRIN ASSOCIATED PERIODIC SYNDROME; CYTOKINE PRODUCTION; DRUG CHOICE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FAMILIAL MEDITERRANEAN FEVER; FEVER; GENE MUTATION; HEREDITARY PERIODIC FEVER; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; INFLAMMATION; INNATE IMMUNITY; MAJEED SYNDROME; MONOGENIC AUTOINFLAMMATORY DISEASE; MUCKLE WELLS SYNDROME; PAPA SYNDROME; PATHOPHYSIOLOGY; PEDIATRIC GRANULOMATOUS ARTHRITIS; REMISSION; RHEUMATOID ARTHRITIS; SAPHO SYNDROME; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; UNSPECIFIED SIDE EFFECT; AUTOIMMUNE DISEASE; GENETICS; IMMUNOLOGY; METABOLISM; REVIEW; SYNDROME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AUTOIMMUNE DISEASES; CYTOKINES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; INTERLEUKIN-1BETA; SYNDROME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 50349102477     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-008-0047-1     Document Type: Article

References (70)

1. A candidate gene for familial Mediterranean fever. The French FMF Consortium. Nat Genet 1997, 17:25-31.
2. The International FMF Consortium: Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 1997, 90:797-807.
3. McDermott MF, Aksentijevich I, Galon J, et al.: Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999, 97:133-144.
4. Drenth JP, van der Meer JW: Hereditary periodic fever. N Engl J Med 2001, 345:1748-1757.
5. Houten SM, Kuis W, Duran M, et al.: Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat Genet 1999, 22:175-177.
6. Aksentijevich I, Nowak M, Mallah M, et al.: De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): A new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002, 46:3340-3348.
7. Feldmann J, Prieur AM, Quartier P, et al.: Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet 2002, 71:198-203.
8. Hoffman HM, Mueller JL, Broide DH, et al.: Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001, 29:301-305.
9. Wise CA, Gillum JD, Seidman CE, et al.: Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 2002, 11:961-969.
10. Miceli-Richard C, Lesage S, Rybojad M, et al.: CARD15 mutations in Blau syndrome. Nat Genet 2001, 29:19-20.
11. Kanazawa N, Okafuji I, Kambe N, et al.: Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome. Blood 2005, 105:1195-1197.
12. Ferguson PJ, Chen S, Tayeh MK, et al.: Homozygous mutations in LPIN2 are responsible for the syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia (Majeed syndrome). J Med Genet 2005, 42:551-557.
13. Lidar M, Livneh A: FamilCal Mediterranean fever: clinical, molecular and management advancements. Neth J Med 2007, 65:318-324.
14. Touitou I, Sarkisian T, Medlej-Hashim M, et al.: Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum 2007, 56:1706-1712.
15. Gershoni-Baruch R, Brik R, Zacks N, et al.: The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum 2003, 48:1149-1155.
16. Infevers: An online database for autoinflammatory mutations. Available at http://fmf.igh.cnrs.fr/ISSAID/infevers/. Accessed February 2008.
17. Tchernitchko DO, Gerard-Blanluet M, Legendre M, et al.: Intrafamilial segregation analysis of the p.E148Q MEFV allele in familial Mediterranean fever. Ann Rheum Dis 2006, 65:1154-1157.
18. Chae JJ, Komarow HD, Cheng J, et al.: Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol Cell 2003, 11:591-604.
19. Martinon F, Aurns K, Tschopp J: The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002, 10:417-426.
20. Chae JJ, Wood G, Masters SL, et al.: The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S A 2006, 103:9982-9987.
21. Yu JW, Fernandes-Alnemri T, Datta P, et al.: Pyrin activates the ASC pyroptosome in response to engagement by autoinflammatory PSTPIP1 mutants. Mol Cell 2007, 28:214-227.
22. Bhat A, Naguwa SM, Gershwin ME: Genetics and new treatment modalities for familial Mediterranean fever. Ann N Y Acad Sci 2007, 1110:201-208.
23. Williamson LM, Hull D, Mehta R, et al.: Familial Hibernian fever. Q J Med 1982, 51:469-480.
24. Hull KM, Shoham N, Chae JJ, et al.: The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations. Curr Opin Rheumatol 2003, 15:61-69.
25. Lobito AA, Kimberley FC, Muppidi JR, et al.: Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood 2006, 108:1320-1327.
26. Drewe E, Huggins ML, Morgan AG, et al.: Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology (Oxford) 2004, 43:1405-1408.
27. Simon A, Bodar EJ, van der Hilst JC, et al.: Beneficial response to interleukin 1 receptor antagonist in traps. Am J Med 2004, 117:208-210.
28. Kile RL, Rusk HA: A case of cold urticaria with unusual family history. JAMA 1940, 114: 1067-1068.
29. Muckle TJ, Wells M: Urticaria, dAafness, and amyloidosis: a new heredo-familial syndrome. Q J Med 1962, 31:235-248.
30. Muckle TJ: The 'Muckle-Wells' syndrome. Br J Dermatol 1979, 100:87-92.
31. Ansell MB, Bywaters EG, Elderkin FM: Familial arthropathy with rash, uveitis and mental retardation. Proc R Soc Med 1975, 68:584-585.
32. Prieur AM, Griscelli C: Arthropathy with rash, chronic meningitis, eye lesions, and mental retardation. J Pediatr 1981, 99:79-83.
33. Hill SC, Namde M, Dwyer A, et al.: Arthropathy of neonatal onset multisystem inflammatory disease (NOMID/CINCA). Pediatr Radiol 2007, 37:145-152.
34. Aksentijevich I, Putnam D, Remmers EF, et al.: The clinical continuum of cryopyrinopathies: Novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 2007, 56:1273-1285.
35. Goldbach-Mansky R, Dailey NJ, Canna SW, et al.: Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006, 355:581-592.
36. Prieur AM, Griscelli C, Lampert F, et al.: A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients. Scand J Rheumatol Suppl 1987, 66:57-68.
37. Neven B, Callebaut I, Prieur AM, et al.: Molecular basis of the spectral expression of CIAS1 mutations associated with phagocytic cell-mediated autoinflammatory disorders CINCA/NOMID, MWS, and FCU. Blood 2004, 103:2809-2815.
38. Hoffman HM, Gregory SG, Mueller JL, et al.: Fine structure mapping of CIAS1: Identification of an ancestral haplotype and a common FCAS mutation, L353P. Hum Genet 2003, 112:209-216.
39. Saito M, Nishikomori R, Kambe N, et al.: Disease-associated CIAS1 mutations induce monocyte death, revealing low-level mosaicism in mutation-negative cryopyrin-associated periodic syndrome patients. Blood 2008, 111:2132-2141.
40. Jesus AA, Silva CA, Segundo GR, et al.: Phenotypegenotype analysis of cryopyrin-associated periodic syndromes (CAPS): Description of a rare non-exon 3 and a novel CIAS1 missense mutation. J Clin Immunol 2007, 28:134-138.
41. Medzhitov R, Janeway CA Jr: Decoding the patterns of self and nonself by the innate immune system. Science 2002, 296:298-300.
42. McDermott MF, Tschopp J: From inflammasomes to fevers, crystals and hypertension: How basic research explains inflammatory diseases. Trends Mol Med 2007, 13:381-388.
43. O'Connor W Jr, Harton JA, Zhu X, et al.: Cutting edge: CIAS1/cryopyrin/ PYPAF1/NALP3/CATERPILLER 1.1 is an inducible inflammatory mediator with NF-kappa B suppressive properties. J Immunol 2003, 171:6329-6333.
44. Wang L, Manji GA, Grenier JM, et al.: PYPAF7, a novel PYRIN-containing Apaf1-like protein that regulates activation of NF-kappa B and caspase-1-dependent cytokine processing. J Biol Chem 2002, 277:29874-29880.
45. Caroli F, Pontillo A, D'Osualdo A, et al.: Clinical and genetic characterization of Italian patients affected by CINCA syndrome. Rheumatology (Oxford) 2007, 46:473-478.
46. Hawkins PN, Lachmann HJ, Aganna E, McDermott MF: Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004, 50:607-612.
47. Hoffman HM, Rosengren S, Boyle DL, et al.: Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004, 364:1779-1785.
48. Hoffman HM, Throne ML, Amar NJ, et al.: Efficacy and safety of rilonacept (IL-1 trap) in cryopyrin-associated periodic fever syndromes (CAPS): Results from two sequential placebo-controlled studies. Arthritis Rheum, in press.
49. Goldbach-Mansky R, Shroff S, Wilson M, et al.: A pilot study to evaluate the safety and efficacy of the long-acting IL-1 inhibitor, rilonacept (IL-1 Trap) in patients with familial cold autoinflammatory syndrome (FCAS). Arthritis Rheum, in press.
50. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD): Online Mendelian Inheritance in Man, OMIM. Accessed February 8, 2008. Available at http://www.ncbi.nlm.nih.gov/omim.
51. McTaggart SJ: Isoprenylated proteins. Cell Mol Life Sci 2006, 63:255-267.
52. Simon A, van der Meer JW: Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes. Am J Physiol Regul Integr Comp Physiol 2007, 292:R86-R98.
53. Frenkel J, Rijkers GT, Mandey SH, et al.: Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 2002, 46:2794-2803.
54. Simon A, Drewe E, van der Meer JW, et al.: Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther 2004, 75:476-483.
55. Bodar EJ, van der Hilst JC, Drenth JP, et al.: Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: Introducing a vaccination provocation model. Neth J Med 2005, 63:260-264.
56. Demirkaya E, Caglar MK, Waterham HR, et al.: A patient with hyper-IgD syndrome responding to anti-TNF treatment. Clin Rheumatol 2007, 26:1757-1759.
57. Takada K, Aksentijevich I, Mahadevan V, et al.: Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 2003, 48:2645-2651.
58. Lindor NM, Arsenault TM, Solomon H, et al.: A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin Proc 1997, 72:611-615.
59. Shoham NG, Centola M, Mansfield E, et al.: Pyrin binds the PSTPIP1/ CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci U S A 2003, 100:13501-13506.
60. Cortis E, De Benedetti F, Insalaco A, et al.: Abnormal production of tumor necrosis factor (TNF)-alpha and clinical efficacy of the TNF inhibitor etanercept in a patient with PAPA syndrome [corrected]. J Pediatr 2004, 145:851-855.
61. Rose CD, Wouters CH, Meiorin S, et al.: Pediatric granulomatous arthritis: An international registry. Arthritis Rheum 2006, 54:3337-3344.
62. Blau EB: Familial granulomatous arthritis, iritis, and rash. J Pediatr 1985, 107:689-693.
63. Becker ML, Rose CD: Blau syndrome and related genetic disorders causing childhood arthritis. Curr Rheumatol Rep 2005, 7:427-433.
64. Arostegui JI, Arnal C, Merino R, et al.: NOD2 gene-associated pediatric granulomatous arthritis: Clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum 2007, 56:3805-3813.
65. Ferguson PJ, El Shanti HI: Autoinflammatory bone disorders. Curr Opin Rheumatol 2007, 19:492-498.
66. El Shanti HI, Ferguson PJ: Chronic recArrent multifocal osteomyelitis: a concise review and genetic update. Clin Orthop Relat Res 2007, 462:11-19.
67. Medzhitov R: Recognition of microorganisms and activation of the immune response. Nature 2007, 449:819-826.
68. Ye Z, Ting JP: NLR, the nucleotide-binding domain leucinerich repeat containing gene family. Curr Opin Immunol 2008, 20:3-9.
69. Schneider DS: Plant immuWity and film noir: what gumshoe detectives can teach us about plant-pathogen interactions. Cell 2002, 109:537-540.
70. James LC, Keeble AH, Khan Z, et al.: Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function. Proc Natl Acad Sci U S A 2007, 104:6200-6205.